Named as an RFK/MAHA sponsor, and a third party confirms for the first time that peptides launch this year
A Politico report on 21 Sep named HIMS as one of the corporate sponsors of RFK's MAHA movement. It is also the first third-party confirmation that HIMS is preparing to launch peptide products this year. That is a key step:
Read more
the timeline for high-margin peptides moves from narrative to a concrete milestone, which would counter the core problem of branded GLP-1 volume pushing gross margin down from 76% to 64%. But it also exposes a double-edged bet on regulatory alignment and reputation. Paying for access to senior health officials during a sensitive compliance period (the FTC lawsuit of 29 Jul and the securities class action of 3 Sep) is itself a new governance risk. The core tension is unchanged: fast revenue growth (+38% year on year) against earnings quality and compliance costs eroding from both sides. The next proof point is still whether Q4 delivers a jump in profit. Risk/reward leans cautious.
Key evidence
- Politico, 21 Sep: an RFK-linked non-profit raised money from companies in exchange for access to senior health officials. Bloomberg separately confirmed the group asked companies for about $300,000 for access to top health department officials at a summit.
- The list of peptide sponsors names HIMS explicitly (alongside Noom and Wells Pharmacy) and says it is 'preparing to offer peptides later this year'. This is the first third-party confirmation.
- In July the PCAC advisory committee recommended adding 6 of 7 peptides (including BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon) to the 503A compounding list. The decision rests with FDA/HHS (headed by RFK), and FDA has not yet formally adopted it.
- The Q2 results on 10 Aug confirmed that branded GLP-1 volume pushed gross margin down from 76% to 64%. Peptides are the in-house, high-margin line that bulls value most.
- A compliance overhang runs in parallel: the FTC lawsuit of 29 Jul and the securities class action filed on 3 Sep. They now stand in fresh contrast with HIMS actively moving closer to regulators.
- SEC check: the latest 8-K is still the Q2 results of 10 Aug. The four Form 4 filings on 17-18 Sep are all pre-arranged 10b5-1 sales, and there are no new company announcements.
Catalysts to watch
- Whether FDA/HHS formally adds the 6 PCAC-recommended peptides to the 503A compounding list. If it does, HIMS benefits from its head start.
- An announcement from HIMS confirming the peptide launch this year, and the first SKUs
- Whether the Q4 profit jump materialises (and management's timing on the high-margin peptide line)
- How the public and regulatory backlash to the MAHA sponsorship story develops, and whether it triggers new compliance scrutiny or attention from Congress
Risks
- The story of paying for access to senior health officials is a new reputational and governance risk during the sensitive compliance period around the FTC lawsuit and the class action
- If the 6 peptides are not added to 503A, or are delayed, the bulls' core high-margin narrative loses its anchor
- If the pressure that took gross margin from 76% to 64% widens further in Q3 or Q4, it would offset the peptide story
- The MAHA link itself could invite regulatory backlash, or risk from a change in the political cycle
Sources 5
- Politico, 21 Sep: report on RFK/MAHA corporate sponsors
- Bloomberg: MAHA non-profit's $300,000 price for access
- HIMS Q2 results, 10 Aug (gross margin down from 76% to 64%)
- HIMS 8-K and Form 4 filings (17-18 Sep), SEC check
- FTC lawsuit of 29 Jul and securities class action filed on 3 Sep
A brief is a lead for our research, not a verified conclusion or advice.